{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:00:57Z","timestamp":1787238057072,"version":"build-2736575974"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["IJU Case Reports"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In addition to reduced nectin\u20104 expression, the upregulation of ATP\u2010binding cassette transporters has been suggested as a potential mechanism of resistance to enfortumab vedotin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 76\u2010year\u2010old man previously treated with platinum\u2010containing chemotherapy and pembrolizumab for metastatic bladder cancer was administered enfortumab vedotin because of disease progression. Subsequently, metastasectomy was performed for oligometastatic lesions (in the lung and adrenal gland) that exhibited growth during enfortumab vedotin therapy. Immunostaining analysis revealed decreased nectin\u20104 expression and elevated MDR1, MRP1, and BCRP expression in the metastatic lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Decreased nectin\u20104 expression and increased ATP\u2010binding cassette transporter expression are potential factors in the development of enfortumab vedotin resistance in urothelial carcinoma. Immunohistochemical evaluation of these proteins may aid in predicting treatment efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/iju5.12696","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T20:34:13Z","timestamp":1706560453000},"page":"173-176","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Increased expression of\n                    <scp>ATP<\/scp>\n                    \u2010binding cassette transporters in enfortumab vedotin\u2010resistant urothelial cancer"],"prefix":"10.1002","volume":"7","author":[{"given":"Mariko","family":"Kotono","sequence":"first","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-9294","authenticated-orcid":false,"given":"Toshiki","family":"Kijima","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Takada\u2010Owada","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kurashina","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Kokubun","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7086-6964","authenticated-orcid":false,"given":"Takao","family":"Kamai","sequence":"additional","affiliation":[{"name":"Department of Urology Dokkyo Medical University  Shimotsuga Tochigi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4175"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0013"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14736"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1984"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2265572"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0408"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000938"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184411"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"e_1_2_12_14_1","first-page":"3221","article-title":"Characterization of chemoresistance mechanisms in a series of cisplatin\u2010resistant transitional carcinoma cell lines","volume":"20","author":"Hour TC","year":"2000","journal-title":"Anticancer Res."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1536-7"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0036"}],"container-title":["IJU Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iju5.12696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T04:27:08Z","timestamp":1709440028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iju5.12696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/iju5.12696"],"URL":"https:\/\/doi.org\/10.1002\/iju5.12696","archive":["Portico"],"relation":{},"ISSN":["2577-171X","2577-171X"],"issn-type":[{"value":"2577-171X","type":"print"},{"value":"2577-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"2023-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}